Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer

[1]  R. Manchanda.  Special Issue “Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer” , 2022, Cancers.

[2]  Dmitry A. Kulikov,et al.  Proteomic and molecular dynamic investigations of PTM-induced structural fluctuations in breast and ovarian cancer , 2021, Scientific Reports.

[3]  M. Parmar,et al.  Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial , 2021, The Lancet.

[4]  P. Pinsky,et al.  General population screening for ovarian cancer , 2021, The Lancet.

[5]  S. Haque,et al.  CD19 Chimeric Antigen Receptor-Exosome Targets CD19 Positive B-lineage Acute Lymphocytic Leukemia and Induces Cytotoxicity , 2021, Cancers.

[6]  D. Chan,et al.  Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors* , 2018, Molecular & Cellular Proteomics.

[7]  Hsien-Da Huang,et al.  dbPTM in 2019: exploring disease association and cross-talk of post-translational modifications , 2018, Nucleic Acids Res..

[8]  E. Wine,et al.  The Complex Interplay between Chronic Inflammation, the Microbiome, and Cancer: Understanding Disease Progression and What We Can Do to Prevent It , 2018, Cancers.

[9]  Giuseppe Troiano,et al.  The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review) , 2017, International journal of molecular medicine.

[10]  Alicia Llorente,et al.  Lipids in exosomes: Current knowledge and the way forward. , 2017, Progress in lipid research.

[11]  D. Donoghue,et al.  The importance of regulatory ubiquitination in cancer and metastasis , 2017, Cell cycle.

[12]  Rong Biaoxue,et al.  Increased serum amyloid A as potential diagnostic marker for lung cancer: a meta-analysis based on nine studies , 2016, BMC Cancer.

[13]  S. Orrù,et al.  Mass Spectrometry-Based Metabolomic and Proteomic Strategies in Organic Acidemias , 2016, BioMed research international.

[14]  Gary D Bader,et al.  Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer , 2016, Genome Medicine.

[15]  C. Théry,et al.  Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes , 2016, Proceedings of the National Academy of Sciences.

[16]  S. Batra,et al.  Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy. , 2015, Cancer Research.

[17]  T. Curry,et al.  Ovarian cancer: involvement of the matrix metalloproteinases. , 2015, Reproduction.

[18]  S. Batra,et al.  Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments , 2015, Scientific Reports.

[19]  Xinping Gao,et al.  Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification , 2015, Journal of Ovarian Research.

[20]  M. Matzuk,et al.  The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice. , 2015, Endocrinology.

[21]  K. Rodland,et al.  Proteomics of ovarian cancer: functional insights and clinical applications , 2015, Cancer and Metastasis Reviews.

[22]  Zhen-hua Hu,et al.  Expression of hMOF in different ovarian tissues and its effects on ovarian cancer prognosis. , 2015, Oncology reports.

[23]  G. Calin,et al.  The fusion of two worlds: Non-coding RNAs and extracellular vesicles - diagnostic and therapeutic implications (Review) , 2014, International journal of oncology.

[24]  Clotilde Théry,et al.  Biogenesis and secretion of exosomes. , 2014, Current opinion in cell biology.

[25]  I. Meinhold-Heerlein,et al.  The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer , 2014, Archives of Gynecology and Obstetrics.

[26]  V. Adam,et al.  MALDI-TOF MS as evolving cancer diagnostic tool: a review. , 2014, Journal of pharmaceutical and biomedical analysis.

[27]  Xifeng Dong,et al.  Advances in tumor markers of ovarian cancer for early diagnosis. , 2014, Indian journal of cancer.

[28]  D. Lu,et al.  Expression of serum amyloid A in uterine cervical cancer , 2014, Diagnostic Pathology.

[29]  H. Husi,et al.  Classical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications. , 2014, Bioanalysis.

[30]  Lynda Chin,et al.  Identification of Double-stranded Genomic DNA Spanning All Chromosomes with Mutated KRAS and p53 DNA in the Serum Exosomes of Patients with Pancreatic Cancer* , 2014, The Journal of Biological Chemistry.

[31]  Yu-Chieh Wang,et al.  Protein post-translational modifications and regulation of pluripotency in human stem cells , 2013, Cell Research.

[32]  Xin Zhou,et al.  Prognostic value of MMP-9 in ovarian cancer: a meta-analysis. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[33]  R. Kalluri,et al.  Exosomes in tumor microenvironment influence cancer progression and metastasis , 2013, Journal of Molecular Medicine.

[34]  Graça Raposo,et al.  Extracellular vesicles: Exosomes, microvesicles, and friends , 2013, The Journal of cell biology.

[35]  A. Tessitore,et al.  Serum Biomarkers Identification by Mass Spectrometry in High-Mortality Tumors , 2013, International journal of proteomics.

[36]  Peer Bork,et al.  Deciphering a global network of functionally associated post-translational modifications , 2012, Molecular systems biology.

[37]  Han-Wei Lin,et al.  Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. , 2012, The Biochemical journal.

[38]  D. Denhardt,et al.  Osteopontin: role in immune regulation and stress responses. , 2011, Cytokine & growth factor reviews.

[39]  S. Hassan,et al.  Protein kinase D1 suppresses epithelial-to-mesenchymal transition through phosphorylation of snail. , 2010, Cancer research.

[40]  N. Vasudev,et al.  Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer , 2010, British Journal of Cancer.

[41]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[42]  L. Wells,et al.  Identification of candidate biomarkers with cancer‐specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis , 2010, Proteomics.

[43]  L. Frati,et al.  HE4: a new potential early biomarker for the recurrence of ovarian cancer , 2010, Tumor Biology.

[44]  C. Rancourt,et al.  MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells , 2010, Molecular Cancer.

[45]  Baris E. Suzek,et al.  The Universal Protein Resource (UniProt) in 2010 , 2009, Nucleic Acids Res..

[46]  D.G. Knorre,et al.  Chemical and Functional Aspects of Posttranslational Modification of Proteins , 2009, Acta naturae.

[47]  E. Hoffman,et al.  Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. , 2009, The Journal of clinical investigation.

[48]  T. Yip,et al.  Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology , 2009, Acta obstetricia et gynecologica Scandinavica.

[49]  M. Parmar,et al.  Recruitment to multicentre trials—lessons from UKCTOCS: descriptive study , 2008, BMJ : British Medical Journal.

[50]  H. Tsujimoto,et al.  Verification of measurement of the feline serum amyloid A (SAA) concentration by human SAA turbidimetric immunoassay and its clinical application. , 2008, The Journal of veterinary medical science.

[51]  S. Gendler,et al.  Structure and function of the cell surface (tethered) mucins. , 2008, Annual review of physiology.

[52]  B. Têtu,et al.  Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. , 2008, American journal of clinical pathology.

[53]  E. Kohn,et al.  Ovarian cancer in the proteomics era , 2008, International Journal of Gynecologic Cancer.

[54]  Nicole Urban,et al.  CA125 in ovarian cancer. , 2007, Biomarkers in medicine.

[55]  Daniel W Chan,et al.  Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. , 2007, Gynecologic oncology.

[56]  A. Fertala,et al.  Type I collagen and collagen mimetics as angiogenesis promoting superpolymers. , 2007, Current pharmaceutical design.

[57]  A. Sahni,et al.  Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor‐2 (FGF‐2) , 2007, Journal of thrombosis and haemostasis : JTH.

[58]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.

[59]  R. Drapkin,et al.  The distal fallopian tube: a new model for pelvic serous carcinogenesis , 2007, Current opinion in obstetrics & gynecology.

[60]  J. Garber,et al.  A candidate precursor to serous carcinoma that originates in the distal fallopian tube , 2007 .

[61]  Chih-Hung Ku,et al.  Evaluation of Serum Amyloid A as a Biomarker for Gastric Cancer , 2006, Annals of Surgical Oncology.

[62]  H. Frierson,et al.  Comprehensive analysis of HE4 expression in normal and malignant human tissues , 2006, Modern Pathology.

[63]  Christopher P Crum,et al.  The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.

[64]  S. Steinberg,et al.  Proteomic Analysis of Malignant Ovarian Cancer Effusions as a Tool for Biologic and Prognostic Profiling , 2006, Clinical Cancer Research.

[65]  R. Berkowitz,et al.  Proteomic-Based Discovery and Characterization of Glycosylated Eosinophil-Derived Neurotoxin and COOH-Terminal Osteopontin Fragments for Ovarian Cancer in Urine , 2006, Clinical Cancer Research.

[66]  Alan T. Remaley,et al.  Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer , 2006, Clinical Cancer Research.

[67]  Juri Rappsilber,et al.  Exploring the hidden human urinary proteome via ligand library beads. , 2005, Journal of proteome research.

[68]  E. Kohn,et al.  SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics. , 2005, Pharmacogenomics.

[69]  Victor G Zgoda,et al.  Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1 , 2005, Proteomics.

[70]  Liliana Gheorghiu,et al.  Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands , 2005, Electrophoresis.

[71]  Mitchell Ho,et al.  New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA , 2005, Clinical Cancer Research.

[72]  H. Lilja,et al.  The evolution of a genetic locus encoding small serine proteinase inhibitors. , 2005, Biochemical and biophysical research communications.

[73]  Mitchell Ho,et al.  Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients , 2005, Clinical Cancer Research.

[74]  H. Moutsopoulos,et al.  Salivary gland epithelial cell exosomes: A source of autoantigenic ribonucleoproteins. , 2005, Arthritis and rheumatism.

[75]  Christopher P Crum,et al.  Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. , 2005, Cancer research.

[76]  J. Castle,et al.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs , 2005, Nature.

[77]  Mamoru Fukuda,et al.  Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2. , 2005, Cancer research.

[78]  Cathy H. Wu,et al.  The Universal Protein Resource (UniProt) , 2004, Nucleic Acids Res..

[79]  N Urban,et al.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. , 2004, Gynecologic oncology.

[80]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[81]  Ira Pastan,et al.  Mesothelin: a new target for immunotherapy. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[82]  N. Blom,et al.  Prediction of post‐translational glycosylation and phosphorylation of proteins from the amino acid sequence , 2004, Proteomics.

[83]  A. Chambers,et al.  Role of osteopontin in tumour progression , 2004, British Journal of Cancer.

[84]  E. Diamandis.  Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[85]  Y. Matsuo,et al.  Solution Structure of the SEA Domain from the Murine Homologue of Ovarian Cancer Antigen CA125 (MUC16)* , 2004, Journal of Biological Chemistry.

[86]  N. Umesaki,et al.  Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion* , 2004, Journal of Biological Chemistry.

[87]  E. Diamandis.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.

[88]  L. Liotta,et al.  Use of proteomic analysis to monitor responses to biological therapies , 2004, Expert opinion on biological therapy.

[89]  A. Musk,et al.  Mesothelin-family proteins and diagnosis of mesothelioma , 2003, The Lancet.

[90]  R. Kryscio,et al.  Risk of Malignancy in Unilocular Ovarian Cystic Tumors Less Than 10 Centimeters in Diameter , 2003, Obstetrics and gynecology.

[91]  A. Pothen,et al.  Protocols for disease classification from mass spectrometry data , 2003, Proteomics.

[92]  E. Diamandis.  Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? , 2003, Clinical chemistry.

[93]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[94]  R. Schwartz.  The hypereosinophilic syndrome and the biology of cancer. , 2003, The New England journal of medicine.

[95]  G. Johnson,et al.  Ubiquitylation of MEKK1 Inhibits Its Phosphorylation of MKK1 and MKK4 and Activation of the ERK1/2 and JNK Pathways* , 2003, The Journal of Biological Chemistry.

[96]  H. Lilja,et al.  A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. , 2002, The Biochemical journal.

[97]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[98]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[99]  T. O'brien,et al.  The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences , 2001, Tumor Biology.

[100]  R. Kryscio,et al.  Ovarian volume related to age. , 2000, Gynecologic oncology.

[101]  M. Fernández-Aceñero,et al.  Prognostic influence of tumor‐associated eosinophilic infiltrate in colorectal carcinoma , 2000, Cancer.

[102]  I. Konishi,et al.  Review: Gonadotropins and Development of Ovarian Cancer , 1999, Oncology.

[103]  Z. Ye,et al.  Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[104]  H. Rosenberg,et al.  The eosinophil ribonucleases , 1998, Cellular and Molecular Life Sciences CMLS.

[105]  C. Kirchhoff.  Molecular characterization of epididymal proteins. , 1998, Reviews of reproduction.

[106]  Keith D Wilkinson,et al.  BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression , 1998, Oncogene.

[107]  E. Thomson,et al.  Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: I. Hereditary Nonpolyposis Colon Cancer , 1997 .

[108]  H. Cantor,et al.  The immunology of Eta-1/osteopontin. , 1996, Cytokine & growth factor reviews.

[109]  F. D. de Beer,et al.  Human serum amyloid A (SAA) protein: a prominent acute‐phase reactant for clinical practice , 1996, European journal of clinical investigation.

[110]  I. Pastan,et al.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[111]  N. Yamaguchi,et al.  Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNA (*) , 1995, The Journal of Biological Chemistry.

[112]  P. Bork,et al.  The SEA module: A new extracellular domain associated with O‐glycosylation , 1995, Protein science : a publication of the Protein Society.

[113]  M. A. Davitz,et al.  How GPI-anchored proteins turnover: or where do they go after arrival at the plasma membrane. , 1994, Seminars in immunology.

[114]  P. Kruk,et al.  Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. , 1992, American journal of obstetrics and gynecology.

[115]  R. Sakakibara,et al.  Characterization of a unique nonsecretory ribonuclease from urine of pregnant women. , 1992, Journal of biochemistry.

[116]  R. Ivell,et al.  A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. , 1991, Biology of reproduction.

[117]  T. Saga,et al.  Normal bronchial mucus contains high levels of cancer‐associated antigens, CA125, CA19‐9, and carcinoembryonic antigen , 1990, Cancer.

[118]  A. Kobata,et al.  Fractionation by lectin affinity chromatography indicates that the glycosylation of most ribonucleases in human viscera and body fluids is organ specific. , 1986, Archives of biochemistry and biophysics.

[119]  F. Hanisch,et al.  Ca 125 and Ca 19-9: two cancer-associated sialylsaccharide antigens on a mucus glycoprotein from human milk. , 1985, European journal of biochemistry.

[120]  R. Bast,et al.  Tissue Distribution of a Coelomic- Epithelium‐Related Antigen Recognized by the Monoclonal Antibody OC125 , 1983, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[121]  R. Bast,et al.  Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.

[122]  H. Husi,et al.  Methods in capillary electrophoresis coupled to mass spectrometry for the identification of clinical proteomic/peptidomic biomarkers in biofluids. , 2015, Methods in molecular biology.

[123]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[124]  E. Kohn,et al.  Proteomic analysis for the early detection and rational treatment of cancer--realistic hope? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[125]  N. Fedarko,et al.  Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. , 2004, Journal of the National Cancer Institute.

[126]  F. Kikkawa,et al.  Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125. , 1995, Gynecologic and obstetric investigation.

[127]  N V Belinskaia,et al.  [Early detection of ovarian cancer]. , 1978, Voprosy onkologii.